A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

IT’S become one of the most popular weight loss drugs on the market, with pharmacies estimating that at least 1.5 million people in the UK are already using it. The jab, which is offered privately ...

Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

A new study involving nearly 1.7 million patients suggests that semaglutide — a drug that mimics a gut hormone to lower blood sugar and aid weight loss — could significantly cut dementia risk in older ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...

GLP-1 agonists like Ozmepic may provide protection against dementia. A recent study suggests that semaglutide, found in ...